Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, 100021, China.
Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, 100021, China; Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, 100021, China.
Eur J Radiol. 2021 Aug;141:109823. doi: 10.1016/j.ejrad.2021.109823. Epub 2021 Jun 10.
No comparative study on evaluating performance of radiological criteria has been investigated in metastatic colorectal cancer (mCRC) patients treated with the combination of Regorafenib and anti-programmed cell death 1(PD-1) antibody. We aimed to compare the performance of different radiological criteria in evaluating response in mCRC patients treated with the combination of Regorafenib plus anti-PD-1 antibody.
We retrospectively recruited patients treated with Regorafenib and anti-PD-1 antibody in a single institution. Baseline and the first tumor evaluation of contrast-enhanced computed tomography (CE-CT) were assessed by three evaluation criteria: RECIST 1.1, Choi, modified Choi (mChoi). Overall survival (OS) was defined as endpoint event.
Twenty-three mCRC patients [age: 58.8 ± 10.6 years, 18 (78.3 %) males] were assessed. The median overall survival was 11.8 months. According to RECIST 1.1, 8 (34.8 %) patients were stable disease (SD) and 15 (65.2 %) were progressive disease (PD). According to Choi and mChoi, 5 (21.7 %) and 1(4.3 %) patient was responders, respectively. All non-PD patients showed significantly better overall survival than PD patients by all criteria. According to Choi, those identified as responders showed better overall survival than non-responders though significant statistics were not reached (P=0.262).
RECIST 1.1, Choi and mChoi criteria could identify survival benefit from Regorafenib plus anti-PD-1 antibody in mCRC patients. However, the value of responders detected by Choi remains to be validated in further studies.
在接受瑞戈非尼联合抗程序性死亡 1（PD-1）抗体治疗的转移性结直肠癌（mCRC）患者中，尚未研究评估影像学标准性能的比较研究。我们旨在比较瑞戈非尼联合抗 PD-1 抗体治疗的 mCRC 患者中不同影像学标准在评估疗效中的表现。
我们回顾性招募了在一家单中心接受瑞戈非尼和抗 PD-1 抗体治疗的患者。基线和第一次增强 CT（CE-CT）肿瘤评估采用三种评估标准：RECIST 1.1、Choi、改良 Choi（mChoi）。总生存期（OS）定义为终点事件。
23 例 mCRC 患者[年龄：58.8±10.6 岁，18 例（78.3%）男性]被评估。中位总生存期为 11.8 个月。根据 RECIST 1.1，8 例（34.8%）患者为疾病稳定（SD），15 例（65.2%）为疾病进展（PD）。根据 Choi 和 mChoi，分别有 5 例（21.7%）和 1 例（4.3%）患者为缓解者。所有非 PD 患者的总生存期均明显优于所有标准的 PD 患者。根据 Choi，被确定为缓解者的患者总生存期优于非缓解者，但无显著统计学意义（P=0.262）。
RECIST 1.1、Choi 和 mChoi 标准可识别瑞戈非尼联合抗 PD-1 抗体治疗 mCRC 患者的生存获益。然而，Choi 检测到的缓解者的价值尚需进一步研究验证。
Zotero 插件